222. Primary nephrotic syndrome Clinical trials / Disease details
Clinical trials : 310 / Drugs : 295 - (DrugBank : 117) / Drug target genes : 63 - Drug target pathways : 194
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2200058162 | 2022-05-01 | 2022-03-31 | Efficacy of CRS model combining serum anti-PLA2R antibody and GRS score for diagnosis and prognosis of iMN | Efficacy of CRS model combining serum anti-PLA2R antibody and GRS score for diagnosis and prognosis of iMN | Idiopathic membranous nephropathy | Gold Standard:Chronic kidney disease was first diagnosed according to the presence of edema, proteinuria, hypoproteinemia, hyperlipidemia, etc. Kidney biopsy was performed on the basis of chronic kidney disease to obtain kidney tissue, and then pathological examination was performed to confirm the diagnosis of primary nephrotic syndrome;Index test:Serum creatinine, serum albumin, cholesterol, triglyceride, high density lipoprotein, low density lipoprotein, serum IgG, serum IgA, serum IgM, complement C3, complement C4 were determined by blood sampling. 24 hours proteinuria was measured by urine retention. The renal tissue was sectionized, and the pathological diagno; | Yuebei People’s Hospital | NULL | Pending | 18 | Both | Target condition:50;Difficult condition:50 | China | ||
| 2 | ChiCTR2100050481 | 2021-09-01 | 2021-08-27 | Clinical study of liquid biopsy in membranous nephropathy based on urine exosomal proteome detection | Clinical study of liquid biopsy in membranous nephropathy based on urine exosomal proteome detection | membranous nephropathy | Gold Standard:kidney biopsy;Index test:types and amounts of proteins expressed in exosomes; | Shenzhen Second People's Hospital | NULL | Recruiting | 18 | 90 | Both | Target condition:100;Difficult condition:200 | China | |
| 3 | ChiCTR2000037467 | 2020-12-31 | 2020-08-28 | Effect of Tripterygium wilfordii polyglycoside tablets on the inhibition of TM on complement pathway and related inflammatory markers in membranous nephropathy | The complement pathway and related inflammatory factor markers in the treatment of idiopathic membranous nephropathy | idiopathic membranous nephropathy | Gold Standard:Cell hemolysis test;Index test:Immunochemiluminescence (ECL) and flow cytometry (FCM) were used to determine the activity of each complement pathway and the target of complement; Complement hemolysis test is usually used to determine the activity of total complement and single complement component, but it is difficult to be applied to clinical ; | Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine | NULL | Pending | 18 | 80 | Both | Target condition:40;Difficult condition:40 | China | |
| 4 | NCT04387448 (ClinicalTrials.gov) | July 28, 2020 | 11/5/2020 | A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease | A Phase 2a Multiple Ascending, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease | Kidney Diseases;Diabetic Nephropathies;Glomerulosclerosis, Focal Segmental;Nephrosis, Lipoid;Urologic Diseases;Diabetes Complications;Diabetes Mellitus;Endocrine System Diseases;Glomerulonephritis;Nephritis;Nephrosis | Drug: GFB-887;Drug: Placebo | Goldfinch Bio, Inc. | NULL | Terminated | 18 Years | 75 Years | All | 96 | Phase 2 | United States |
| 5 | ChiCTR1900027128 | 2019-10-30 | 2019-11-01 | Validation of Anti-Phospholipase A2 Receptor Antibody ELISA in a Chinese Cohort With Idiopathic Membranous Nephropathy: a Multicenter Observational Study | The Cut-off Value of Anti-Phospholipase A2 Receptor Antibody ELISA in Chinese Patients | Membranous Nephrology | Gold Standard:Pathological diagnosis according to kidney biopsy(Chapter 7, 7.1 Evaluation of MN, KDIGO 2012);Index test:Serum PLA2R Antibody by ELISA; | Department of Nephrology, The First Affiliated Hospital of Shandong First Medical University | NULL | Recruiting | Both | Target condition:288;Difficult condition:290 | N/A | China |